黄花夹竹桃甙及其与氮芥合用的体内抗肿瘤活性  

Antitumor activity of thevetoside alone and in combination with chlormethine in vivo

作　　者：章雄文[1] 黄自强[1] 李常春[1] 

机构地区：[1]福建医学院药理教研室

出　　处：《中国药理学报》1994年第3期285-288,共4页Acta Pharmacologica Sinica

摘　　要：黄花夹竹桃甙(thevetoside,TS)属强心甙类药,1.5 mg·kg^(-1)·d^(-1)ip治疗小鼠腹水瘤H22,EAC,P388及实体瘤S180,U14,Lewis肺癌,仅对实体瘤有效,抑瘤率为48.7％—56.7％。TS与轻度抑瘤作用剂量(0.3,0.5或1.0 mg·kg^(-1)·d^(-1))的氮芥合用,抑瘤活性高于单独给药组,能使腹水瘤小鼠的生存期延长率达到82.4至>122.1％;对实体瘤的抑瘤率为65.6％—72.5％Thevetoside (TS) is one of the cardiac glycosides. A study of antitumor activity was carried out in 6 types of murine tumors in vivo, such as the ascitic tumors H22, EAC, P388, and solid tumors S180, U14, Lewis lung carcinoma, which were treated with ip TS 1. 5 mg ·kg-1·d-1 alone or in combination with chlormethine (Ch1) 0. 3, 0. 5, or 1.0 mg·kg-1·d-1. TS only showed a remarkable inhibition on the growth of 3 types of solid tumors with inhibition rates of 48. 7% - 56. 7%. The effect of the combination therapy was much pronounced than that of independent administration. The life span under combined therapy was increased 82. 4% to >122. 1%. For solid tumors, the combined administration gave inhibition rates of 65. 6 % -72.5%.

关 键 词：黄花夹竹桃甙 氮芥 肿瘤移植 

分 类 号：R965.2[医药卫生—药理学]